Maynard Um
-
-
-
-
-
-
-
Biodexa enrolls first patients in Phase 3 trial for FAP treatment
-
-
-
-
-
-
-
Biodexa Pharmaceuticals (BDRX) Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study
-
-
-
-
-
-
-
Biodexa Pharmaceuticals (BDRX) Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP
-
-
-
-
-
-
-
Biodexa Pharmaceuticals' (BDRX) MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer
-
-
-
-
-
-
-
Biodexa Pharmaceuticals (BDRX) Prices $5 Million Registered Direct Offering and Concurrent Private Placement
-
-
458,613 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

